In a Phase II trial of tirzepatide, more individuals with T2DM achieved weight loss of ≤5% and ≤10%, and glucose control with the dual GLP‐1R/GIPR agonist than with a GLP‐1R agonist (dulaglutide) alone.131. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.